001     120134
005     20240228135013.0
024 7 _ |a 10.1007/s00401-014-1276-0
|2 doi
024 7 _ |a pmid:24791927
|2 pmid
024 7 _ |a pmc:PMC4059991
|2 pmc
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
037 _ _ |a DKFZ-2017-00717
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Pietsch, Torsten
|b 0
245 _ _ |a Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
260 _ _ |a Berlin
|c 2014
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1490879993_7656
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This study aimed to prospectively evaluate clinical, histopathological and molecular variables for outcome prediction in medulloblastoma patients. Patients from the HIT2000 cooperative clinical trial were prospectively enrolled based on the availability of sufficient tumor material and complete clinical information. This revealed a cohort of 184 patients (median age 7.6 years), which was randomly split at a 2:1 ratio into a training (n = 127), and a test (n = 57) dataset in order to build and test a risk score for this population. Independent validation was performed in a non-overlapping cohort (n = 83). All samples were subjected to thorough histopathological investigation, CTNNB1 mutation analysis, quantitative PCR, MLPA and FISH analyses for cytogenetic variables, and methylome analysis. By univariable analysis, clinical factors (M-stage), histopathological variables (large cell component, endothelial proliferation, synaptophysin pattern), and molecular features (chromosome 6q status, MYC amplification, subgrouping) were found to be prognostic. Molecular consensus subgrouping (WNT, SHH, Group 3, Group 4) was validated as an independent feature to stratify patients into different risk groups. When comparing methods for the identification of WNT-driven medulloblastoma, this study identified CTNNB1 sequencing and methylation profiling to most reliably identify these patients. After removing patients with particularly favorable (CTNNB1 mutation, extensive nodularity) or unfavorable (MYC amplification) markers, a risk score for the remaining 'intermediate molecular risk' population dependent on age, M-stage, pattern of synaptophysin expression, and MYCN copy-number status was identified, with speckled synaptophysin expression indicating worse outcome. Test and independent validation of the score confirmed significant discrimination of patients by risk profile. Methylation subgrouping and CTNNB1 mutation status represent robust tools for the risk stratification of medulloblastoma. A simple clinico-pathological risk score was identified, which was confirmed in a test set and by independent clinical validation.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a CTNNB1 protein, human
|2 NLM Chemicals
650 _ 7 |a MYCN protein, human
|2 NLM Chemicals
650 _ 7 |a N-Myc Proto-Oncogene Protein
|2 NLM Chemicals
650 _ 7 |a Nuclear Proteins
|2 NLM Chemicals
650 _ 7 |a Oncogene Proteins
|2 NLM Chemicals
650 _ 7 |a SYP protein, human
|2 NLM Chemicals
650 _ 7 |a Synaptophysin
|2 NLM Chemicals
650 _ 7 |a beta Catenin
|2 NLM Chemicals
700 1 _ |a Schmidt, Rene
|b 1
700 1 _ |a Remke, Marc
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 3
700 1 _ |a Hovestadt, Volker
|0 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
|b 4
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 5
700 1 _ |a Felsberg, Jörg
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Kaulich, Kerstin
|0 P:(DE-He78)25e258723e7e1ad2ff808b9274d3c479
|b 7
700 1 _ |a Goschzik, Tobias
|b 8
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 9
700 1 _ |a Northcott, Paul A
|0 P:(DE-HGF)0
|b 10
700 1 _ |a von Hoff, Katja
|b 11
700 1 _ |a von Bueren, André O
|b 12
700 1 _ |a Friedrich, Carsten
|b 13
700 1 _ |a Mynarek, Martin
|b 14
700 1 _ |a Skladny, Heyko
|b 15
700 1 _ |a Fleischhack, Gudrun
|b 16
700 1 _ |a Taylor, Michael D
|b 17
700 1 _ |a Cremer, Friedrich
|b 18
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 19
700 1 _ |a Faldum, Andreas
|b 20
700 1 _ |a Reifenberger, Guido
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Rutkowski, Stefan
|b 22
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 23
|e Last author
773 _ _ |a 10.1007/s00401-014-1276-0
|g Vol. 128, no. 1, p. 137 - 149
|0 PERI:(DE-600)1458410-4
|n 1
|p 137 - 149
|t Acta neuropathologica
|v 128
|y 2014
|x 1432-0533
909 C O |o oai:inrepo02.dkfz.de:120134
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)25e258723e7e1ad2ff808b9274d3c479
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 3
920 1 _ |0 I:(DE-He78)L401-20160331
|k L401
|l DKTK Essen
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)L401-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21